NCT05979363

Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.

Study Summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

Want to learn more about this trial?

Request More Info

Interventions

anti-BCMA CAR-TBIOLOGICAL
Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
VRD-based regimenDRUG
Bortezomib, Lenalidomide and Dexamethasone

Study Locations

FacilityCityStateCountry
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjinChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026